Cargando…
Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma
Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate positron emission tomography metrics could be helpful to identify patient...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719066/ https://www.ncbi.nlm.nih.gov/pubmed/33327711 http://dx.doi.org/10.3324/haematol.2020.263194 |
_version_ | 1784624859859386368 |
---|---|
author | Rossi, Cédric Tosolini, Marie Gravelle, Pauline Pericart, Sarah Kanoun, Salim Evrard, Solene Gilhodes, Julia Franchini, Don-Marc Amara, Nadia Syrykh, Charlotte Bories, Pierre Oberic, Lucie Ysebaert, Loïc Martin, Laurent Ramla, Selim Robert, Philippine Tabouret-Viaud, Claire Casasnovas, René-Olivier Fournié, Jean-Jacques Bezombes, Christine Laurent, Camille |
author_facet | Rossi, Cédric Tosolini, Marie Gravelle, Pauline Pericart, Sarah Kanoun, Salim Evrard, Solene Gilhodes, Julia Franchini, Don-Marc Amara, Nadia Syrykh, Charlotte Bories, Pierre Oberic, Lucie Ysebaert, Loïc Martin, Laurent Ramla, Selim Robert, Philippine Tabouret-Viaud, Claire Casasnovas, René-Olivier Fournié, Jean-Jacques Bezombes, Christine Laurent, Camille |
author_sort | Rossi, Cédric |
collection | PubMed |
description | Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate positron emission tomography metrics could be helpful to identify patients with a high risk of treatment failure with rituximab. We retrospectively included a total of 132 untreated FL patients separated into training and validation cohorts. Optimal threshold of baseline whole-body maximum standardized uptake (SUVmax) was first determined in the training cohort (n=48) to predict progression-free survival (PFS). The PET results were investigated along with the tumor and immune microenvironment, which were determined by immunochemistry and transcriptome studies involving gene set enrichment analyses and immune cell deconvolution, together with the tumor mutation profile. We report that baseline SUVmax>14.5 was associated with poorer PFS than baseline SUVmax≤14.5 (hazard ratio =0.28; P=0.00046). Neither immune T-cell infiltration nor immune checkpoint expression were associated with baseline PET metrics. By contrast, FL samples with Ki-67 staining ≥10% showed enrichment of cell cycle/DNA genes (P=0.013) and significantly higher SUVmax values (P=0.007). Despite similar oncogenic pathway alterations in both SUVmax groups of FL samples, four out of five cases harboring the infrequent FOXO1 transcription factor mutation were seen in FL patients with SUVmax>14.5. Thus, high baseline SUVmax reflects FL tumor proliferation and, together with Ki-67 proliferative index, can be used to identify patients at risk of early relapse with rituximab chemotherapy. |
format | Online Article Text |
id | pubmed-8719066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-87190662022-01-14 Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma Rossi, Cédric Tosolini, Marie Gravelle, Pauline Pericart, Sarah Kanoun, Salim Evrard, Solene Gilhodes, Julia Franchini, Don-Marc Amara, Nadia Syrykh, Charlotte Bories, Pierre Oberic, Lucie Ysebaert, Loïc Martin, Laurent Ramla, Selim Robert, Philippine Tabouret-Viaud, Claire Casasnovas, René-Olivier Fournié, Jean-Jacques Bezombes, Christine Laurent, Camille Haematologica Article Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate positron emission tomography metrics could be helpful to identify patients with a high risk of treatment failure with rituximab. We retrospectively included a total of 132 untreated FL patients separated into training and validation cohorts. Optimal threshold of baseline whole-body maximum standardized uptake (SUVmax) was first determined in the training cohort (n=48) to predict progression-free survival (PFS). The PET results were investigated along with the tumor and immune microenvironment, which were determined by immunochemistry and transcriptome studies involving gene set enrichment analyses and immune cell deconvolution, together with the tumor mutation profile. We report that baseline SUVmax>14.5 was associated with poorer PFS than baseline SUVmax≤14.5 (hazard ratio =0.28; P=0.00046). Neither immune T-cell infiltration nor immune checkpoint expression were associated with baseline PET metrics. By contrast, FL samples with Ki-67 staining ≥10% showed enrichment of cell cycle/DNA genes (P=0.013) and significantly higher SUVmax values (P=0.007). Despite similar oncogenic pathway alterations in both SUVmax groups of FL samples, four out of five cases harboring the infrequent FOXO1 transcription factor mutation were seen in FL patients with SUVmax>14.5. Thus, high baseline SUVmax reflects FL tumor proliferation and, together with Ki-67 proliferative index, can be used to identify patients at risk of early relapse with rituximab chemotherapy. Fondazione Ferrata Storti 2020-12-17 /pmc/articles/PMC8719066/ /pubmed/33327711 http://dx.doi.org/10.3324/haematol.2020.263194 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Rossi, Cédric Tosolini, Marie Gravelle, Pauline Pericart, Sarah Kanoun, Salim Evrard, Solene Gilhodes, Julia Franchini, Don-Marc Amara, Nadia Syrykh, Charlotte Bories, Pierre Oberic, Lucie Ysebaert, Loïc Martin, Laurent Ramla, Selim Robert, Philippine Tabouret-Viaud, Claire Casasnovas, René-Olivier Fournié, Jean-Jacques Bezombes, Christine Laurent, Camille Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma |
title | Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma |
title_full | Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma |
title_fullStr | Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma |
title_full_unstemmed | Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma |
title_short | Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma |
title_sort | baseline suvmax is related to tumor cell proliferation and patient outcome in follicular lymphoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719066/ https://www.ncbi.nlm.nih.gov/pubmed/33327711 http://dx.doi.org/10.3324/haematol.2020.263194 |
work_keys_str_mv | AT rossicedric baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT tosolinimarie baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT gravellepauline baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT pericartsarah baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT kanounsalim baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT evrardsolene baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT gilhodesjulia baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT franchinidonmarc baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT amaranadia baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT syrykhcharlotte baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT boriespierre baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT obericlucie baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT ysebaertloic baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT martinlaurent baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT ramlaselim baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT robertphilippine baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT tabouretviaudclaire baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT casasnovasreneolivier baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT fourniejeanjacques baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT bezombeschristine baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma AT laurentcamille baselinesuvmaxisrelatedtotumorcellproliferationandpatientoutcomeinfollicularlymphoma |